Evidence map›Paper›PMID 23431164›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury.

Trent A Watkins, Bei Wang, Sarah Huntwork-Rodriguez, Jing Yang, Zhiyu Jiang, Jeffrey Eastham-Anderson, Zora Modrusan, Joshua S Kaminker, Marc Tessier-Lavigne, Joseph W Lewcock

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 1 synthesis or guideline pooled it, 338 citations in OpenAlex.

  1. Pooled it
  2. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.Annals of clinical and translational neurology · 2022
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Protein kinases as therapeutic targets in Alzheimer's disease: challenges, insights, and new frontiers.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution.

Trent A WatkinsNeurodegeneration Laboratories, Department of Neuroscience, Gentech, Inc., South San Francisco, CA 94080, USA.
Bei Wang
Sarah Huntwork-Rodriguez
Jing Yang
Zhiyu Jiang
Jeffrey Eastham-Anderson
Zora Modrusan
Joshua S Kaminker
Marc Tessier-Lavigne
Joseph W Lewcock
Genentech

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cell intrinsic factors that determine whether a neuron regenerates or undergoes apoptosis in response to axonal injury are not well defined. Here we show that the mixed-lineage dual leucine zipper kinase (DLK) is an essential upstream mediator of both of these divergent outcomes in the same cell type. Optic nerve crush injury leads to rapid elevation of DLK protein, first in the axons of retinal ganglion cells (RGCs) and then in their cell bodies. DLK is required for the majority of gene expression changes in RGCs initiated by injury, including induction of both proapoptotic and regeneration-associated genes. Deletion of DLK in retina results in robust and sustained protection of RGCs from degeneration after optic nerve injury. Despite this improved survival, the number of axons that regrow beyond the injury site is substantially reduced, even when the tumor suppressor phosphatase and tensin homolog (PTEN) is deleted to enhance intrinsic growth potential. These findings demonstrate that these seemingly contradictory responses to injury are mechanistically coupled through a DLK-based damage detection mechanism.

Indexed as

AnimalsApoptosisAxonsMAP Kinase Kinase KinasesMiceMice, Inbred C57BLMice, TransgenicNerve DegenerationNerve RegenerationOptic Nerve InjuriesPTEN PhosphohydrolaseRetinal Ganglion CellsTranscription, GeneticMAP Kinase Kinase Kinasesmitogen-activated protein kinase kinase kinase 12PTEN PhosphohydrolasePten protein, mouse

Identifiers

PMID23431164
PMCPMC3593899
OpenAlexW2068539809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.